 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ZL-1211 / ZAI Lab
Phase classification, Metastases: A Study of ZL-1211 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Sep 2, 2024
P1, N=34, Completed, Sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.
Phase classification: P1/2 --> P1
- ||| ZL-1211 / ZAI Lab
Trial completion, Enrollment change, Trial completion date, Metastases: A Study of ZL-1211 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - May 23, 2024
P1/2, N=34, Completed, Sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.
Phase classification: P1/2 --> P1 Recruiting --> Completed | N=162 --> 34 | Trial completion date: Oct 2024 --> Apr 2024
- || ZL-1211 / ZAI Lab
Trial completion date, Trial primary completion date, Metastases: A Study of ZL-1211 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=162, Recruiting, Sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.
- ZL-1211 / ZAI Lab
Preliminary results of a phase 1/2, first-in-human, open-label, dose escalation study of ZL-1211 (anti-Claudin 18.2 mAb) in patients with unresectable or metastatic solid tumors. (On Demand | Hall A; Poster Bd # 379) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2306;
P1/2
ZL-1211 displayed an acceptable safety/tolerability profile to date and demonstrated preliminary antitumor effects. Clinical trial information: NCT05065710.
- ZL-1211 / ZAI Lab
Clinical translation of biomarkers for ZL-1211, an anti-CLDN18.2 antibody, in patients with advanced solid tumors from a phase I dose-escalation study (Section 44; Poster Board #10) - Mar 14, 2023 - Abstract #AACR2023AACR_5976;
P1/2
Taken together, analytical approaches developed and validated from preclinical studies were successfully translated to characterize clinical samples in the current Phase 1 trial. The exploratory analysis indicated the clinical relevance of multiple biomarkers and their potential as predictive biomarkers of ZL-1211.
- ZL-1211 / ZAI Lab
Anti-CLDN18.2 antibody ZL-1211 enhances anti-tumor activities in combination with chemotherapy in gastric cancer models (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1122;
P1/2
Furthermore, ZL-1211 in combination with SoC chemotherapies, oxaliplatin + capecitabine (CAPOX), enhanced anti-tumor efficacy in SNU601 gastric cancer xenograft model...Conclusions These data provide rationale to combine ZL-1211 with SoC chemotherapy in gastric cancer. Currently, a phase I dose escalation study is underway to assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of ZL-1211 in patients with advanced solid tumors ( NCT05065710 ).
- ZL-1211 / ZAI Lab
ZL-1211 exhibits robust anti-tumor activity by enhancing ADCC and activating innate and adaptive immunity in CLDN18.2-high and -low expressing gastric cancer models (Section 39) - Mar 9, 2022 - Abstract #AACR2022AACR_2809;
P1/2
Taken together, our data suggest that ZL-1211 more effectively targets CLDN18.2-high gastric cancers as well as -low expressing malignancies that are not eligible for treatment with the leading clinical benchmark by inducing a robust ADCC response and activating innate and adaptive immunity to enhance anti-tumor efficacy. Clinical activity of ZL-1211 is currently under evaluation in a Phase I clinical trial (NCT05065710).
- || ZL-1211 / ZAI Lab
Trial initiation date, Metastases: A Study of ZL-1211 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Jan 27, 2022
P1/2, N=162, Recruiting, Sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.
Clinical activity of ZL-1211 is currently under evaluation in a Phase I clinical trial (NCT05065710). Initiation date: Oct 2021 --> Jan 2022
- | ZL-1211 / ZAI Lab
New P1/2 trial, Metastases: A Study of ZL-1211 in Patients With Advanced Solid Tumor (clinicaltrials.gov) - Oct 3, 2021
P1/2, N=162, Recruiting, Sponsor: Zai Biopharmaceutical (Suzhou) Co., Ltd.
- ZL-1211 / ZAI Lab
[VIRTUAL] ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models () - Mar 11, 2021 - Abstract #AACR2021AACR_787;
Together, our data suggest that ZL-1211 might provide therapeutic benefit for a wider spectrum of low- and high-CLDN18.2 expressing tumors than the leading clinical benchmark. A Ph1 dose escalation study to assess the safety and preliminary efficacy of ZL-1211 is planned.